[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-clear-cell-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-clear-cell-adenocarcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100447912","phase-2-testing-nivolumab-with-or-without-ipilimumab-in-deficient-mismatch-repair-system-dmmr-recurrent-endometrial-carcinoma-100447912",false,"NCT05112601","Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma","Inclusion Criteria:\n\n* Patients with measurable or non-measurable (detectable) recurrent endometrial cancer\n* Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined per RECIST 1.1 criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \\>= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be \\>= 15 mm in short axis when measured by CT or MRI\n* Non-measurable (detectable) disease in a patient is defined in this protocol per RECIST 1.1 criteria as one who does not have measurable disease but has at least one of the following conditions:\n\n  * All other lesions (or sites of disease), including small lesions (longest diameter \\\u003C10 mm or pathological lymph nodes with \\>= 10 to \\\u003C 15 mm short axis), are considered non-measurable disease\n  * Ascites and\u002For pleural effusion attributed to tumor\n  * Solid and\u002For cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions\n* Patients must have endometrial cancer with deficient mismatch repair system. All patients must have institutional immunohistochemistry (IHC) and\u002For microsatellite instability (MSI) testing to determine mismatch repair (MMR) status. MMR deficiency is defined as lack of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6, EPCAM) by immunohistochemistry and\u002For presence of microsatellite instability high using the National Cancer Institute (NCI)-5plex and Promega v1.2 assays, or institutional standards (e.g. next-generation sequencing \\[NGS\\] panel)\n\n  * Method(s) of detection of MMR deficiency will be recorded for each patient. An institutional pathology report, and additional reports if available, documenting these results must be submitted. Patients with \"equivocal\" results on MMR testing by immunohistochemistry may be eligible if they have documented evidence of microsatellite instability by MSI testing or by next generation sequencing assays. MMR testing by IHC may be used to resolve equivocal\u002Findeterminate MSI results\n* Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, mucinous adenocarcinoma, dedifferentiated\u002Fundifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)\n* Patients may have received 1-2 prior lines of systemic therapy:\n\n  * Prior anti-PD1\u002FPD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic\u002Frecurrent settings. Patients must have had a complete response and have disease progression\u002Frelapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition\n* Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic\u002Fpara aortic radiation therapy, intravaginal brachytherapy, and\u002For palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration\n* Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to registration\n* Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, biologic agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C)\n* Age \\>= 18\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n* Platelets \\>= 100,000\u002Fmcl\n* Absolute neutrophil count (ANC) \\>= 1,500\u002Fmcl\n* Creatinine =\\\u003C 1.5 x institutional\u002Flaboratory upper limit of normal (ULN)\n* Total serum bilirubin level =\\\u003C 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =\\\u003C3 x ULN may be enrolled)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 3 x ULN\n* Adequate oxygen saturation via pulse oximeter (CTCAE v.5.0 hypoxia \\\u003C grade 2 within 28 days prior to registration)\n* Thyroid-stimulating hormone (TSH) within normal limits (TSH \\\u003C ULN allowed in euthyroid patients on thyroid replacement therapy). TSH testing is only required if clinically indicated\n* Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy. At least 4 weeks must have elapsed since major surgery\n* As clinically indicated, patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better and have a corrected QT (QTc) interval \\\u003C 450 msec\n* The effects of nivolumab, and ipilimumab on the developing human fetus are unknown. For this reason and because nivolumab and ipilimumab are known to be teratogenic, women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception\n\n  * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002FmL\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial\n* Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and the patient is stable off steroids for at least one month\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information\n* Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible\n* Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible\n\nExclusion Criteria:\n\n* Patients with a diagnosis of endometrial serous carcinoma or carcinosarcoma\n* Patients who received prior anti-PD1\u002FPD-L1 therapy and had grade 3-4 or recurring grade 2 immune-related toxicities that led to dose delay or discontinuation of immunotherapy due to those toxicities\n* Patients who received anti-CTLA-4 therapy or other immunotherapeutic agents\n* Patients on chronic steroid therapy except those on replacement therapy at a daily dose of 10mg or less prednisone or equivalent\n* Patients on immunosuppressive therapy, with the exception of:\n\n  * Intra-nasal, inhaled, topical or local steroid injections\n  * Premedication for hypersensitivity reaction\n* Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease\n* Patients with known immune impairment who may be unable to respond to anti-CTLA-4 antibody\n* Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Women who are pregnant or unwilling to discontinue nursing\n* Prior therapy with CTLA-4 inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, and\u002For ipilimumab including severe hypersensitivity reactions to any monoclonal antibody","FEMALE","18 Years",{"count":19,"type":20},81,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.",[26,27,28,29,30,31,32,33,34],"Endometrial Adenocarcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Mucinous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Endometrioid Adenocarcinoma","Recurrent Endometrial Carcinoma","RECRUITING","2026-06-18",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2022-06-02",{"date":43,"type":20},"2032-07-30",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",137,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100443065","determine-the-utility-of-liquid-biopsies-and-tumor-molecular-profiling-in-predicting-recurrence-in-endometrial-cancers-100443065","NCT05049538","Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers","A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer","Inclusion Criteria:\n\n* Women age 18 years and older\n* Histologic diagnosis of endometrial cancer\n* Candidate for primary surgical treatment or has recently had prior primary surgery\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\nPatients who have received prior treatment including chemotherapy or radiation therapy for endometrial cancer. Prior hormonal therapy for the treatment of endometrial cancer is allowed. Patients with prior primary surgery will be allowed to enroll in this trial if the patient has not received any chemotherapy or radiation at the time of enrollment. Note: patients with a history of other cancers may be enrolled after discussion with the PI if it is determined that they are at low risk for recurrence or metastasis.",{"count":56,"type":20},1000,"OBSERVATIONAL","This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and storing samples of blood and tissue from patients with endometrial cancer to study in the laboratory may help doctors learn how the cells in the blood may change during treatment for uterine cancer.",[27,28,31,60,61,62],"Endometrial Serous Adenocarcinoma","Malignant Uterine Neoplasm","Uterine Corpus Carcinosarcoma","2026-04-30",{"date":65,"type":39},"2026-05-06",{"date":67,"type":39},"2019-06-18",{"date":69,"type":20},"2028-06-30",{"name":71,"class":72},"M.D. Anderson Cancer Center","OTHER",1,{"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100318167","phase-3-short-course-vaginal-cuff-brachytherapy-in-treating-participants-with-stage-i-ii-endometrial-cancer-100318167",true,"NCT03422198","Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer","Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)","SAVE","Inclusion Criteria:\n\n* Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated. Carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I and stage II, with one of the following combinations of stage and grade:\n\n  * Stage IA, grade 1 with LVSI, 2, 3\n  * Stage IB, grades 1-3\n  * Stage II, grades 1-3\n  * Stage IIIA, grades 1-3, not receiving EBRT as part of adjuvant therapy.\n* Participants post-hysterectomy and free from residual disease.\n* World Health Organization (WHO)\u002FEastern Cooperative Oncology Group (ECOG)-performance status 0-2.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Life expectancy of \\>2 years.\n\nExclusion Criteria:\n\n* Stages of endometrial carcinoma other than described.\n* Previous pelvic radiotherapy.\n* Concurrent malignancy requiring non-protocol anti-cancer treatment other than surgery.","ALL",{"count":85,"type":20},188,[87],"PHASE3","This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells.\n\nAfter completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.",[27,29,60,90,91,92,93,62,94],"Stage I Uterine Corpus Cancer","Stage IA Uterine Corpus Cancer","Stage IB Uterine Corpus Cancer","Stage II Uterine Corpus Cancer","Uterine Corpus Sarcoma","2025-11-25",{"date":97,"type":39},"2025-12-12",{"date":99,"type":39},"2018-02-02",{"date":101,"type":20},"2029-10-31",{"name":103,"class":72},"University of Utah",5]